Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages

Majumdar, Sadhana; Flasher, Diana L.; Friend, Daniel S.; Nassos, P S; Yajko, D M; Hadley, W K; Düzgüneş, Nejat

doi:10.1128/aac.36.12.2808

Cited by 81 publications

(41 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To what extent infected tissue targeting of the liposomal antibiotics also contributes to the increased therapeutic efficacy in these animal models was not investigated. Other studies showed an increased intracellular penetrating capacity of liposomal fluoroquinolones compared with drugs in the free form (22,23). Leitzke et al compared drug concentrations in a model of Mycobacterium avium infection in lung and liver of mice after administration of amikacin or ciprofloxacin in the free or liposomal form (18).…”

Section: Discussionmentioning

confidence: 99%

Ciprofloxacin in Polyethylene Glycol-Coated Liposomes: Efficacy in Rat Models of Acute or Chronic Pseudomonas aeruginosa Infection

Bakker-Woudenberg

Kate

Guo³

et al. 2002

Antimicrob Agents Chemother

View full text Add to dashboard Cite

In a previous study in experimental Klebsiella pneumoniae pneumonia, the therapeutic potential of ciprofloxacin was significantly improved by encapsulation in polyethylene glycol-coated ("pegylated") long-circulating (STEALTH) liposomes. Pegylated liposomal ciprofloxacin in high doses was nontoxic and resulted in relatively high and sustained ciprofloxacin concentrations in blood and tissues, and hence an increase in the area under the plasma concentration-time curve (AUC). These data correspond to data from animal and clinical studies showing that for fluoroquinolones the AUC/MIC ratio is associated with favorable outcome in serious infections. Clinical failures and the development of resistance are observed for marginally susceptible organisms like Pseudomonas aeruginosa and for which sufficient AUC/MIC ratios cannot be achieved. In the present study the therapeutic efficacy of pegylated liposomal ciprofloxacin was investigated in two rat models of Pseudomonas aeruginosa pneumonia. In the acute model pneumonia developed progressively, resulting in a rapid onset of septicemia and a high mortality rate. Ciprofloxacin twice daily for 7 days was not effective at doses at or below the maximum tolerated dose (MTD). However, pegylated liposomal ciprofloxacin either at high dosage or given at low dosage in combination with free ciprofloxacin on the first day of treatment was fully effective (100% survival). Obviously, prolonged concentrations of ciprofloxacin in blood prevented death of the animals due to early-stage septicemia in this acute infection. However, bacterial eradication from the left lung was not effected. In the chronic model, pneumonia was characterized by bacterial persistence in the lung without bacteremia, and no signs of morbidity or mortality were observed. Ciprofloxacin administered for 7 days at the MTD twice daily resulted in killing of more than 99% of bacteria in the lung; this result can also be achieved with pegylated liposomal ciprofloxacin given once daily. Complete bacterial eradication is never observed.Many in vitro studies as well as studies in animal models of infection and human infections have investigated the efficacy of fluoroquinolones. The area under the plasma concentrationtime curve (AUC) and the peak plasma drug concentration, both in relation to the MIC of the pathogen, have been demonstrated to be of primary importance for successful outcome (33). For example, in several clinical trials in patients with nosocomially acquired pneumonia, a 24-h AUC/MIC ratio of at least 100 to 125 (14, 15, 19) or a peak plasma drug concentration/MIC ratio of 10 or more (26) was closely linked to clinical and microbiological cure in seriously ill patients treated with intravenous ciprofloxacin. Most treatment failures with ciprofloxacin were a consequence of high MIC, low AUC, or both. A peak plasma drug concentration/MIC ratio of 10 or 20 has been shown both in vitro and in vivo to prevent the emergence of resistant mutants during therapy with fluoroquinolones.These observations in clinical s...

show abstract

Section: Discussionmentioning

confidence: 99%

Ciprofloxacin in Polyethylene Glycol-Coated Liposomes: Efficacy in Rat Models of Acute or Chronic Pseudomonas aeruginosa Infection

Bakker-Woudenberg

Kate

Guo³

et al. 2002

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Liposomes can carry both hydrophobic and hydrophilic drugs, have slow clearance rates, 85,86 and may deliver agents at increased concentrations, both in biofilm interfaces 87,88 or phagocytosed by cells harboring intracellular pathogens. [89][90][91][92][93] These specific liposomal characteristics are especially advantageous for antibiotic treatment to counter biofilm formation on medical devices and interfaces.…”

Section: Liposome Delivery To Biofilmsmentioning

confidence: 99%

Prevention and treatment of biofilms by hybrid- and nanotechnologies

Kasimanickam¹,

Ranjan²,

Asokan³

et al. 2013

IJN

View full text Add to dashboard Cite

Bacteria growing as adherent biofilms are difficult to treat and frequently develop resistance to antimicrobial agents. To counter biofilms, various approaches, including prevention of bacterial surface adherence, application of device applicators, and assimilation of antimicrobials in targeted drug delivery machinery, have been utilized. These methods are also combined to achieve synergistic bacterial killing. This review discusses various multimodal technologies, presents general concepts, and describes therapies relying on the principles of electrical energy, ultrasound, photodynamics, and targeted drug delivery for prevention and treatment of biofilms.

show abstract

“…Another interesting approach is the development and use of liposome-encapsulated aminoglycosides (256), used for both local applications (14,227,234,235,325) and intravenous administration (283,285). The activity of liposome-encapsulated aminoglycosides against intracellular microorganisms is of special interest (8,88,97,174,176).…”

Section: Antimicrobial Activity and Clinical Indicationsmentioning

confidence: 99%

Versatility of Aminoglycosides and Prospects for Their Future

2003

View full text Add to dashboard Cite

Aminoglycoside antibiotics have had a major impact on our ability to treat bacterial infections for the past half century. Whereas the interest in these versatile antibiotics continues to be high, their clinical utility has been compromised by widespread instances of resistance. The multitude of mechanisms of resistance is disconcerting but also illuminates how nature can manifest resistance when bacteria are confronted by antibiotics. This article reviews the most recent knowledge about the mechanisms of aminoglycoside action and the mechanisms of resistance to these antibiotics

show abstract

Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages

Cited by 81 publications

References 34 publications

Ciprofloxacin in Polyethylene Glycol-Coated Liposomes: Efficacy in Rat Models of Acute or Chronic Pseudomonas aeruginosa Infection

Ciprofloxacin in Polyethylene Glycol-Coated Liposomes: Efficacy in Rat Models of Acute or Chronic Pseudomonas aeruginosa Infection

Prevention and treatment of biofilms by hybrid- and nanotechnologies

Versatility of Aminoglycosides and Prospects for Their Future

Contact Info

Product

Resources

About